Patents by Inventor Anthony Boitano
Anthony Boitano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11958908Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: November 24, 2020Date of Patent: April 16, 2024Assignee: CRISPR THERAPEUTICS AGInventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Publication number: 20240075157Abstract: Disclosed are antibodies and antibody drug conjugates having an Fc region with substitutions resulting in essentially a silent Fc region. The antibodies and antibody drug conjugates described herein are useful for the depletion of cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting, e.g., a population of CD45+ or CD117+ cancer cells or CD45+ autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: January 18, 2023Publication date: March 7, 2024Inventors: Anthony Boitano, Michael Cooke, Charlotte Fenton McDonagh, Rahul Palchaudhuri, Bradley R. Pearse, Ganapathy N. Sarma
-
Publication number: 20230390412Abstract: Described herein are compositions and methods useful for the depletion of CD45+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder, for instance, by depleting a population of CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for allogeneic hematopoietic stem cell transplant therapy and to improve the engraftment of allogeneic hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: August 17, 2022Publication date: December 7, 2023Inventors: Geoffrey O. Gillard, Jennifer Lynn Proctor, Sharon Hyzy, Anthony Boitano, Michael Cooke
-
Publication number: 20230330185Abstract: The invention relates to the in vivo transduction of hematopoietic stem and progenitor cells (HSPCs) in a subject, such as a human subject, and to the treatment of subjects suffering from various pathologies, such as blood diseases, metabolic disorders, cancers, and autoimmune diseases, among others.Type: ApplicationFiled: April 27, 2021Publication date: October 19, 2023Inventors: Anthony Boitano, Kevin A. Goncalves, Dwight Morrow, Andre Lieber, Hans-Peter Kiem, Michael P. Cooke
-
Publication number: 20230130646Abstract: Described herein are compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a subject, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the composition and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others.Type: ApplicationFiled: May 12, 2022Publication date: April 27, 2023Inventors: Dwight Morrow, Patrick C. Falahee, Anthony Boitano, Michael P. Cooke, Kevin A. Goncalves
-
Patent number: 11572411Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: November 17, 2020Date of Patent: February 7, 2023Assignee: Magenta Therapeutics, Inc.Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Publication number: 20220401481Abstract: The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others.Type: ApplicationFiled: October 30, 2020Publication date: December 22, 2022Inventors: Anthony Boitano, Michael P. Cooke, John C. Davis, Patrick C. Falahee, Kevin A. Goncalves, Sharon Hyzy, Dwight Morrow, Jason Neale, Glen Raffel, William Savage, Veit Schmelmer
-
Publication number: 20220273811Abstract: Disclosed are methods and compositions relating to the treatment of autoimmune diseases using anti-CD45 antibody drug conjugates (ADCs).Type: ApplicationFiled: December 3, 2021Publication date: September 1, 2022Inventors: Geoffrey O. Gillard, Jennifer Lynn Proctor, Anthony Boitano, Michael Cooke
-
Publication number: 20220267441Abstract: Disclosed are anti-CD45 antibodies, antigen binding fragments thereof, and antibody drug conjugates (ADCs) that specifically bind to human CD45. Such antibodies and ADCs are useful in therapeutic methods, including methods of depleting CD45+ cells from a patient. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy, and to improve the engraftment of hematopoietic stem cell transplants, by selectively depleting endogenous CD45+ cells prior to the transplant procedure.Type: ApplicationFiled: October 22, 2021Publication date: August 25, 2022Inventors: Anthony Boitano, Michael Cooke, Charlotte Fenton McDonagh, Rahul Palchaudhuri, Rajiv Panwar, Bradley Pearse, Paul Fredrick Widboom, Patricia Ann Cruite
-
Publication number: 20220249683Abstract: Provided herein are methods of depleting T cells for therapeutic uses, including administration of anti-CD2 or anti-CD5 antibody drugs conjugates (ADCs) for treatment. Provided are anti-CD2 ADCs or anti-CD5 ADCs for use as agents to treat a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. The compositions and methods described can be used to deplete populations of CD2+ or CD5+ cells, such as CD2+ or CD5+ cancer cells or CD2+ or CD5+ immune cells, and can also be used to prepare a patient for hematopoietic stem cell transplantation or solid organ transplantation.Type: ApplicationFiled: December 3, 2021Publication date: August 11, 2022Inventors: Anthony Boitano, Michael Cooke, Sean Mcdonough, Jennifer Lynn Proctor
-
Publication number: 20220226493Abstract: Antibody-drug conjugates (ADCs) comprising an anthracycline and an anti-CD117 antibody are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, are provided.Type: ApplicationFiled: October 21, 2021Publication date: July 21, 2022Inventors: Charlotte Fenton McDonagh, Anthony Boitano, Michael Cooke, Ganapathy N. Sarma, Rajiv Panwar
-
Publication number: 20220175944Abstract: Anti-CD117 antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, are provided.Type: ApplicationFiled: October 21, 2021Publication date: June 9, 2022Inventors: Charlotte F. McDonagh, Anthony Boitano, Michael Cooke, Ganapathy N. Sarma, Rajiv Panwar
-
Publication number: 20220175951Abstract: The invention provides anti-CD45 antibody drug conjugates (ADCs), and methods of use thereof. In one embodiment, the invention provides methods of depleting a population of CD45+ cells from a subject, by administration of an anti-CD45 ADC provided herein. In some embodiments, the ADCs include a cytotoxin containing a benzodiazepine moiety, for example. a pyrrolobenzodiazepine (PBD) or an indolinobenzodiazepine (IGN) moiety.Type: ApplicationFiled: October 22, 2021Publication date: June 9, 2022Inventors: Anthony Boitano, Michael Cooke, Geoffrey O. Gillard, Charlotte Fenton McDonagh, Rahul Palchaudhuri, Bradley R. Pearse
-
Publication number: 20220177577Abstract: Anti-CD117 antibody-drug conjugates (ADCs) comprising calicheamicin and are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, are provided.Type: ApplicationFiled: October 22, 2021Publication date: June 9, 2022Inventors: Charlotte Fenton McDonagh, Anthony Boitano, Michael Cooke, Ganapathy N. Sarma, Rajiv Panwar
-
Publication number: 20220177578Abstract: The present disclosure provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: October 22, 2021Publication date: June 9, 2022Inventors: Rahul Palchaudhuri, Anthony Boitano, Michael Cooke, Bradley R. Pearse
-
Publication number: 20220177575Abstract: The present disclosure provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: October 22, 2021Publication date: June 9, 2022Inventors: Rahul Palchaudhuri, Anthony Boitano, Michael Cooke, Bradley R. Pearse
-
Publication number: 20220175946Abstract: The disclosure provides compositions and methods useful for the depletion of a specific population of endogenous hematopoietic stem cells and/or immune cells from a subject prior to transplantation with genetically modified stem cells to improve the engraftment of the transplanted stem cells and provide gene therapy. The disclosure provides compositions and methods for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ or CD45+ cells in a patient, such as a human.Type: ApplicationFiled: October 21, 2021Publication date: June 9, 2022Inventors: Anthony BOITANO, Michael Cooke, Rahul Palchaudhuri, Bradley R. Pearse
-
Publication number: 20220096559Abstract: The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. In certain embodiments, the compositions and methods described herein lead to the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft vs. host disease.Type: ApplicationFiled: May 7, 2021Publication date: March 31, 2022Inventors: Dwight Morrow, Patrick C. Falahee, Anthony Boitano, Michael P. Cooke, Kevin A. Goncalves
-
Publication number: 20220062339Abstract: The invention provides methods of depleting CD45+ cells in human patients undergoing chimeric antigen receptor (CAR) immunotherapy in order to promote acceptance of CAR expressing immune cells. Anti-CD45 antibody drug conjugates (ADCs) are administered as a conditioning regimen to a human patient receiving autologous or allogeneic CAR expressing immune cells such that the CAR expressing immune cells are accepted by the human patient. Compositions and methods of the invention can be used in combination with CAR therapy to treat a variety of pathologies, including autoimmune diseases and cancer.Type: ApplicationFiled: July 6, 2021Publication date: March 3, 2022Inventors: Michael Cooke, Geoffrey O. Gillard, Anthony Boitano
-
Patent number: 11260079Abstract: The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. In certain embodiments, the compositions and methods described herein lead to the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft vs. host disease.Type: GrantFiled: March 13, 2019Date of Patent: March 1, 2022Assignee: Magenta Therapeutics, Inc.Inventors: Dwight Morrow, Patrick C. Falahee, Anthony Boitano, Michael P. Cooke, Kevin A. Goncalves